Weight Loss Wales at Obesity Week 2026: De-escalation of GLP-1 Therapy — Real-World Data

This is the second of three posts covering the original research posters presented by Dr Alun Davies of Weight Loss Wales at Obesity Week 2026 in Washington DC on 13 November 2026.

The de-escalation challenge in obesity medicine

GLP-1 receptor agonist therapies have transformed the treatment of obesity. Clinical trials have demonstrated substantial, sustained weight loss in patients receiving these agents, and real-world data from services like Weight Loss Wales have confirmed that these outcomes are achievable outside the controlled conditions of a clinical trial. But a question that has received comparatively little attention — and that is of enormous practical importance to clinicians and patients alike — is what happens when treatment is reduced or stopped.

De-escalation of GLP-1 therapy occurs for a range of reasons: side effects, cost, patient preference, clinical decision-making around maintenance, or supply constraints. The published literature on de-escalation is sparse, and most of what exists comes from clinical trials rather than real-world practice. The second poster presented by Dr Davies at Obesity Week 2026 addresses this gap with original data from Weight Loss Wales.

What the data examine

The analysis characterises the clinical circumstances, patient profiles, and weight outcomes associated with dose reduction or treatment discontinuation in patients managed through Weight Loss Wales. It is the first real-world dataset from a UK remote obesity clinic to examine de-escalation systematically.

Key questions addressed by the data include:

• Under what clinical circumstances does de-escalation occur — and how does this vary between patients?
• What weight outcomes are observed following dose reduction versus full discontinuation?
• Are there identifiable predictors of successful de-escalation — defined as maintained weight loss — versus weight regain?
• What does this tell us about the optimal timing and approach to de-escalation in clinical practice?

Why de-escalation data matter

The question of how and when to de-escalate GLP-1 therapy is one of the most pressing practical challenges in obesity medicine. Obesity is a chronic disease — the 2023 Nature Medicine consensus statement and the frameworks of the European Association for the Study of Obesity (EASO) and the World Obesity Federation are unambiguous on this point. Like other chronic diseases, it typically requires long-term management rather than a fixed course of treatment followed by discontinuation.

Yet the reality of clinical practice is that de-escalation does occur — and when it does, clinicians need evidence-based guidance on how to manage it. The Weight Loss Wales dataset provides a real-world foundation for developing structured de-escalation protocols that minimise the risk of weight regain while responding to the legitimate clinical and practical reasons that make de-escalation necessary.

Implications for the field

The findings from this poster contribute to an emerging evidence base on the long-term management of obesity as a chronic condition. They support the development of:

• Structured de-escalation pathways within remote and community obesity services
• Evidence-based criteria for identifying patients who are most likely to maintain weight loss following de-escalation
• Protocols for intensified monitoring and support during and after de-escalation
• Patient education resources that set realistic expectations about the risk of weight regain when treatment is reduced

The full poster is available to download from our Advice for Clinicians page. Healthcare professionals interested in our outcome data or CPD training are welcome to contact Dr Davies directly. Patients considering medical weight management can book a consultation with Weight Loss Wales.